Bionomics Investor Presentation Deck
Targeting a Large Segment of the Anxiety Market/Market Size
No FDA-approved fast-acting medications for as-needed treatment
$2,000
$1,750
$1,500
$1,250
$1,000
$750
$500
$250
$0
Bionomics
BNC210 US Social Anxiety Disorder Sales ($M)
247
1,092
1,506
2029
1,662
2026
2032
2035
BNC210 could achieve $1.7B in US
annual peak sales in SAD*
~7M
Opportunity
for BNC210
~18M
36% of adults
SAD symptoms
> 10 years
Sources:
US Census Bureau. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html
NIMH. "Social Anxiety Disorder" data from 2017 National Comorbidity Survey (NCS). https://www.nimh.nih.gov/health/statistics/social-anxiety-disorder.shtml
Anxiety and Depression Association of America (ADAA). "Social Anxiety Disorder - Understand the Facts" https://adaa.org/understanding-anxiety/social-anxiety-disorder
*For forecast assumptions and methods see appendix
*Based on 3rd party market analysis
31M
7.1%
prevalence
in adults
12.1% of adults
at some point in
their lives
6View entire presentation